CN107106685A - 协同澳瑞他汀组合 - Google Patents

协同澳瑞他汀组合 Download PDF

Info

Publication number
CN107106685A
CN107106685A CN201580054253.XA CN201580054253A CN107106685A CN 107106685 A CN107106685 A CN 107106685A CN 201580054253 A CN201580054253 A CN 201580054253A CN 107106685 A CN107106685 A CN 107106685A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
cancer
australia
auspicious statin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580054253.XA
Other languages
English (en)
Chinese (zh)
Inventor
P.萨普拉
B.肖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN107106685A publication Critical patent/CN107106685A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580054253.XA 2014-10-10 2015-09-29 协同澳瑞他汀组合 Pending CN107106685A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062192P 2014-10-10 2014-10-10
US62/062192 2014-10-10
PCT/IB2015/057457 WO2016055907A1 (en) 2014-10-10 2015-09-29 Synergistic auristatin combinations

Publications (1)

Publication Number Publication Date
CN107106685A true CN107106685A (zh) 2017-08-29

Family

ID=54288858

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580054253.XA Pending CN107106685A (zh) 2014-10-10 2015-09-29 协同澳瑞他汀组合

Country Status (12)

Country Link
US (1) US10617670B2 (https=)
EP (2) EP3204005A1 (https=)
JP (1) JP6784668B2 (https=)
KR (1) KR20170058432A (https=)
CN (1) CN107106685A (https=)
AU (1) AU2015329625B2 (https=)
BR (1) BR112017006113A8 (https=)
CA (1) CA2907878A1 (https=)
IL (1) IL251619B (https=)
MX (1) MX2017004580A (https=)
RU (1) RU2717570C2 (https=)
WO (1) WO2016055907A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315415A (zh) * 2017-10-05 2020-06-19 索尼公司 可编程的聚合药物
CN111712511A (zh) * 2017-11-30 2020-09-25 森托瑞恩生物制药公司 澳瑞他汀e衍生物的白蛋白结合产物
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
US12270812B2 (en) 2016-04-06 2025-04-08 Sony Group Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
US12275851B2 (en) 2018-03-21 2025-04-15 Sony Group Corporation Polymeric tandem dyes with linker groups
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
US12391833B2 (en) 2018-06-27 2025-08-19 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
US12473433B2 (en) 2020-12-07 2025-11-18 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
US12577403B2 (en) 2016-04-01 2026-03-17 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US12606588B2 (en) 2019-09-30 2026-04-21 Sony Group Corporation Nucleotide probes

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
EP3455300A1 (en) 2016-05-11 2019-03-20 Sony Corporation Ultra bright dimeric or polymeric dyes
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
US12539334B2 (en) 2018-01-12 2026-02-03 Sony Group Corporation Phosphoalkyl polymers comprising biologically active agents
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
JP7556194B2 (ja) * 2019-12-13 2024-09-26 Ｔｏｐｐａｎホールディングス株式会社 細胞構造体及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938046A (zh) * 2003-11-06 2007-03-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US20110301334A1 (en) * 2010-06-08 2011-12-08 Sunil Bhakta Cysteine engineered antibodies and conjugates
CN103561759A (zh) * 2010-10-22 2014-02-05 西雅图遗传学公司 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463615C (en) 2001-10-30 2011-07-26 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
EP1928912A4 (en) * 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
US7523124B2 (en) 2006-06-26 2009-04-21 Nielsen Media Research, Inc. Methods and apparatus for improving data warehouse performance
PT2074122E (pt) 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
RU2490025C2 (ru) 2007-10-02 2013-08-20 Чугаи Сейяку Кабусики Кайся Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
LT2294072T (lt) 2008-05-23 2017-06-12 Wyeth Llc Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai
WO2012131527A1 (en) 2011-04-01 2012-10-04 Wyeth Llc Antibody-drug conjugates
MX2014004991A (es) * 2011-10-28 2014-05-22 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma.
CN104185477B (zh) * 2011-11-17 2017-05-24 辉瑞公司 细胞毒性肽及其抗体‑药物缀合物
CA2890571A1 (en) * 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938046A (zh) * 2003-11-06 2007-03-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US20110301334A1 (en) * 2010-06-08 2011-12-08 Sunil Bhakta Cysteine engineered antibodies and conjugates
CN103561759A (zh) * 2010-10-22 2014-02-05 西雅图遗传学公司 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT MALLON等: "Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor", 《CLINICAL CANCER RESEARCH》 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12577403B2 (en) 2016-04-01 2026-03-17 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US12270812B2 (en) 2016-04-06 2025-04-08 Sony Group Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
US12560612B2 (en) 2016-04-06 2026-02-24 Sony Group Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
US12461106B2 (en) 2016-04-06 2025-11-04 Sony Group Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
US12145956B2 (en) 2017-10-05 2024-11-19 Sony Group Corporation Programmable polymeric drugs
CN111315415A (zh) * 2017-10-05 2020-06-19 索尼公司 可编程的聚合药物
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
US12098161B2 (en) 2017-10-05 2024-09-24 Sony Group Corporation Programmable polymeric drugs
CN111712511A (zh) * 2017-11-30 2020-09-25 森托瑞恩生物制药公司 澳瑞他汀e衍生物的白蛋白结合产物
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
US12275851B2 (en) 2018-03-21 2025-04-15 Sony Group Corporation Polymeric tandem dyes with linker groups
US12319817B2 (en) 2018-03-21 2025-06-03 Sony Group Corporation Polymeric tandem dyes with linker groups
US12391833B2 (en) 2018-06-27 2025-08-19 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
US12606588B2 (en) 2019-09-30 2026-04-21 Sony Group Corporation Nucleotide probes
US12473433B2 (en) 2020-12-07 2025-11-18 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Also Published As

Publication number Publication date
US20180228769A1 (en) 2018-08-16
RU2017112048A (ru) 2018-11-15
US10617670B2 (en) 2020-04-14
CA2907878A1 (en) 2016-04-10
EP3549583A1 (en) 2019-10-09
JP2017530983A (ja) 2017-10-19
MX2017004580A (es) 2017-06-27
EP3204005A1 (en) 2017-08-16
BR112017006113A8 (pt) 2018-04-24
AU2015329625B2 (en) 2018-04-05
RU2017112048A3 (https=) 2019-05-07
JP6784668B2 (ja) 2020-11-11
WO2016055907A1 (en) 2016-04-14
IL251619B (en) 2020-10-29
IL251619A0 (en) 2017-06-29
KR20170058432A (ko) 2017-05-26
AU2015329625A1 (en) 2017-04-13
BR112017006113A2 (pt) 2017-12-19
RU2717570C2 (ru) 2020-03-24

Similar Documents

Publication Publication Date Title
JP6784668B2 (ja) 相乗的オーリスタチン組合せ
JP2024161445A (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
US11266654B2 (en) Apilimod compositions and methods for using same
TW202216208A (zh) 抗體-藥物結合物及atr抑制劑之組合
EP3923941A1 (en) Pharmaceutical combination comprising tno155 and ribociclib
RU2738934C2 (ru) Способы лечения рака с использованием апилимода
TW202216209A (zh) 抗體-藥物結合物及atm抑制劑之組合
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
KR20120115237A (ko) 암 치료 방법 및 조성물
US20180078561A1 (en) Active metabolites of apilimod and uses thereof
JP2022174200A (ja) 医薬組成物
JP2022533100A (ja) Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
HK1242995A1 (en) Synergistic auristatin combinations
Weber Molecular inhibitors of growth signals
EA049478B1 (ru) Комбинация конъюгата антитела и лекарственного средства и ингибитора atr

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242995

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1242995

Country of ref document: HK